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Diphencyprone (DPCP) is a potent topical sensitizing agent that has been used since the late 1970s by physicians
for the treatment of alopecia areata (AA), viral warts (human papillomavirus) and cutaneous metastases of
melanoma. Although to date the compound is not approved as a drug by the FDA or EMA, physicians have
continued to use DPCP because of its proven effects in these dermatological conditions. The use of the drug has
been highly variable because of differences in compounding, and as a result, the literature reports vary widely in
the concentrations used for sensitization and challenge treatment with DPCP. The efficacy of DPCP has generally
been ascribed to immunological reactions by the host. Inducing inflammation with a contact sensitizer is
counterintuitive to treating AA, an autoimmune disorder. We have hypothesized that the body’s attempt to
downregulate the inflammation caused by the contact sensitizer may also ameliorate AA. Studies using
microarray and miRNA profiling may provide information about how DPCP induces inflammation in human
skin at different times. Gene targets and microRNAs identified through these data may be modulated by an RNA
interference approach to enhance DPCP efficacy and response rates. In addition, this approach may result in the
discovery and development of drugs that are more potent and selective for the treatment of AA.
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Alopecia areata (AA) is an autoimmune disease, present in
B2% of the population (Safavi et al., 1995), in which hair is
lost from some or all areas of the body, usually from the scalp.
AA is a result of the body’s failure to recognize its own cells as
self in the hair follicles, resulting in destruction of its own
tissue as if it were an invader. In 1–2% of cases, AA can
spread to the entire scalp (alopecia totalis) or to the entire
body (alopecia universalis).
Treatment of AA continues to be an issue with very few
treatments providing a sustainable effect. Initial treatment
usually consists of topical and injected corticosteroids. These
treatments, however, show limited success. Topical steroids
take a long time to show benefits, and local injections with
corticosteroids have not provided reproducible efficacy. Other
treatments used occasionally with success are topical irritants
such as anthralin and coal tar, or topical use of immunomo-
dulators such as cyclosporine. Recently Janus kinase inhibitors
administered orally or topically have shown some promise
(Xing et al., 2014).
Happle et al. (1983), reported on the treatment of 27
patients with AA, using a topical contact-sensitizing agent,
diphencyprone (also called diphenylcyclopropenone) or
abbreviated as DPCP. In contrast to another contact-
sensitizing chemical tested in AA, dinitrochlorobenzene,
DPCP passes preclinical genetic-toxicity tests. Data from this
study demonstrated a good clinical outcome in about 75% of
AA patients treated. As a result many other dermatology
groups have published additional studies with DPCP for the
treatment of AA, and have confirmed the results reported in
the original publication (Cotellessa et al., 2001; Avgerinou
et al., 2008; Ohlmeier et al., 2012; Chiang, et al., 2014).
These centers have followed the originally described treatment
approach, i.e., causing a contact-sensitization reaction with a
higher concentration of DPCP on some part of the skin of the
patient, followed by regular once- or twice-weekly treatments
with a lower concentration of DPCP on the area of the scalp
affected by AA. Most of the studies used DPCP in an acetone
solution at concentrations ranging from 1 to 4% DPCP to
cause the initial contact-sensitization reaction. This was
followed by treatments using much lower concentrations,
sometimes starting from as low as 0.001% DPCP and
gradually increasing until a clinical erythema reaction was
observed. Since the initial studies in AA, sensitization
treatment with DPCP has also been tested in other skin
diseases such as warts (Suh et al., 2014), cutaneous
metastases of melanoma (Damian et al., 2014), and other
solid tumors. DPCP has demonstrated significant clinical
benefit in these diseases as well.
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The use of various DPCP concentrations, as well as the
variability in formulations has resulted in a confusing situation
for both the treating physicians and the patients. An additional
factor holding back more widespread use of DPCP is that even
30 years after the first publication by Happle et al. (1983), no
company has undertaken the initiative to try and develop
DPCP according to the regulatory standards for drug
development. This deficiency has resulted in a situation
where one of the most effective and more widely used
treatments for AA is not a registered drug but a chemical
that is purchased from a chemical catalogue and is
compounded by pharmacists for use by the dermatologists.
Seven years ago the first investigational new drug (IND)
Application was submitted to the US FDA for DPCP treatment
of warts, AA, and cutaneous metastasis of solid tumors. This
IND describes DPCP that is formulated in a non-volatile gel
vehicle, which allows for the use of lower concentrations
(0.4% DPCP) for the initial contact-sensitizing dose due in part
to its more viscous nature. The subsequent weekly treatments
are done with a 0.04% DPCP concentration in the same gel
formulation. A first Phase 2 proof of concept study in patients
with non-genital warts demonstrated a clinical benefit in
subjects treated with the DPCP gel formulation compared
with subjects treated with placebo (unpublished results). A
second pilot study was started for treatment of cutaneous
metastases of melanoma and other solid tumors (in addition to
the standard systemic antineoplastic treatment for these
tumors). A third study protocol for treatment of AA with this
new gel formulation of DPCP is expected to begin in the
coming months.
It is counterintuitive that a proinflammatory mediator such
as DPCP would ameliorate an autoimmune disorder such as
AA. One hypothesis is that in response to DPCP treatment, the
body will attempt to downregulate inflammation through a
variety of pathways, resulting in a downregulation of the
autoimmune response at the hair follicle. To investigate
this, Gulati et al. (2014), have performed microarray and
microRNA profiling in skin biopsies of delayed-type
hypersensitivity reactions to DPCP or placebo applications
on the skin of volunteers. This work demonstrated that DPCP,
compared with placebo, caused upregulation of several genes,
as well as downregulation of other genes. The top five
upregulated genes 3 days post DPCP exposure were, in
order of magnitude, serpin pepsidase inhibitor B4, calcium-
binding protein A7A, defensin b4A, MMP-1, and MMP12. On
day 3 post DPCP exposure, the levels of these genes were
between 150 and 340 times higher than with placebo. On day
14 post exposure, DPCP-treated volunteers showed increases
in expression of those genes between 5 and 17 times higher
than in placebo-treated volunteers. The top 5 downregulated
genes 3 days post DPCP exposure were, in order of
magnitude, IL37, ATPase 1A2, growth differentiating factor
10, sarcoglycan G, and myocilin. On day 3 post DPCP
exposure these genes were downregulated 29- to 46-fold
compared with placebo, and between two to sevenfold at
day 14 post DPCP exposure.
These data demonstrate the complexity of the delayed-type
hypersensitivity response induced by treatment with DPCP.
Gene targets identified through these data may be modulated
by an RNA interference (RNAi) approach to enhance DPCP
efficacy and response rates. Evidence for the utility of this
approach includes publications showing that RNAi can
improve efficacy of doxyrubicin, TAX, 5FU, cisplatin, and
other drugs (Sandhu et al., 2012; Cortes-Dericks et al., 2013).
Thus we are proposing that RNAi has potential for
improvement of topical dermatologic products as well. RNAi
has already shown benefit in vivo for Pachonycia Congenita
(Leachman et al., 2008), targeting a mutant allele of KRT6A,
the most commonly affected PC keratin. We propose that an
RNAi approach may be used to improve the known efficacy of
DPCP for warts, AA, and cutaneous metastases of melanoma,
as well as several other conditions. In addition, this approach
may result in the discovery and development of drugs that are
more potent and selective for the treatment of AA. Along these
lines, recent developments in the antisense and RNAi space
could lead to potent compounds that downregulate these
targets, offering even safer and more selective treatment
possibilities for these diseases. The recent work with self-
delivering RNAi compounds (sd-rxRNA; Byrne et al., 2013)
could bring such more-targeted treatment approaches closer
to clinical reality.
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